FDA APPROVED KITE'S YESCARTA FOR NON-HODGKIN'S LYMPHOMA; GILEAD'S SHARE ROSE

Oct 18, 2017

Kite Pharma's Yescarta obtained FDA's green light to treat patients with certain forms of non-Hodgkin's lymphoma (NHL). The good news boosted Gilead's stock price by 2%. Gilead acquired Kite just last month for nearly $12 billion. 

Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin's lymphoma (NHL), accounting for three out of every five cases. In the United States each year, there are approximately 7,500 patients with refractory DLBCL who are eligible for CAR-T cell therapy.

​

As the second in class CAR T cell treatment on market, Yescarta is priced at a hefty $373,000 for one-time treatment.

​

For more information about CAR T cell therapy, here is my blog article.